{
    "clinical_study": {
        "@rank": "45060", 
        "arm_group": [
            {
                "arm_group_label": "A: standard risk group", 
                "arm_group_type": "Experimental", 
                "description": "This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies."
            }, 
            {
                "arm_group_label": "B: high risk group", 
                "arm_group_type": "Experimental", 
                "description": "This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out whether the addition of blood stem cells from a\n      close family member, when added to two units of umbilical cord blood will make the\n      transplant safer."
        }, 
        "brief_title": "Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Leukemia", 
            "Myelodysplastic Syndrome", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Lymphoma", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Note: protocol eligible patients according to the criteria outlined below will then be\n        divided according to age, diagnosis, performance status, organ function, prior\n        transplantation, hematopoietic cell transplant comorbidity index (HCT-CI)23, and CB TNC\n        dose into those who are at standard risk (Arm A) or high risk (Arm B) for early\n        post-transplant death for the purposes of applying stopping rules and outcome analysis.\n\n        Age:\n\n        o 2 - 70 years.\n\n        Diagnosis of high risk hematological malignancy:\n\n        Any acute leukemia in first complete remission (CR) considered at high risk for relapse,\n        or second or third CR, or relapse/refractory less than 25% blasts in bone marrow, or\n        aplasia post-therapy. This includes de novo acute leukemia or acute leukemia that is\n        therapy related or arising from an antecedent hematologic disorder including\n        myelodysplasia (MDS), chronic myeloid leukemia (CML) or other myeloproliferative disorder.\n\n          -  Juvenile myelomonocytic leukemia (JMML) in CR, or relapse with less than 25% bone\n             marrow blasts.\n\n          -  CML with tyrosine kinase inhibitor failure in chronic or accelerated phase or evolved\n             to acute leukemia.\n\n          -  MDS with life-threatening cytopenia(s), and/or red blood cell or platelet transfusion\n             dependence, or patients with aplasia, or patients with excess blasts less than 25%\n             blasts in the bone marrow at work-up.\n\n          -  Aggressive lymphoma: patients in CR1 with disease at high risk of relapse or CR2-3 or\n             PR1-3.\n\n          -  Indolent lymphoma or chronic lymphocytic leukemia (CLL): any disease status provided\n             any transformed component is in CR.\n\n          -  Hodgkin's lymphoma that is primary refractory or relapsed not suitable for other\n             therapy.\n\n        Performance status:\n\n          -  Karnofsky score > or = to 70 or Lansky score > or = to 70.\n\n             \u2022 Organ function:\n\n          -  Left ventricular ejection fraction (LVEF) > or = to 50%.\n\n          -  Spirometry & corrected DLCO > or = to 50% predicted. In small children use history\n             and physical and CT scan to determine pulmonary status.\n\n          -  Total bilirubin < than or = to 1.5 ULN (unless benign congenital elevated bilirubin);\n             ALT/ AST < than or = to 2.5 x upper limit of normal (ULN).\n\n          -  Calculated creatinine (calc. creat.) clearance > than or = to 60 ml/min.\n\n          -  Albumin > than or = to 3.0.\n\n        Graft:\n\n        o Cryopreserved dose will be > than or = to 1.5 x 107 TNC/kilogram in each unit for double\n        unit CB grafts. This will be the CB graft for the majority of patients.\n\n        In select pediatric patients with access to CB units that have high TNC (> 5.0 x 10^7/kg),\n        good HLA-match (5/6 or 6/6) and are from good quality CB banks a single unit could be\n        considered with a back-up CB unit on standby.\n\n          -  In select patients who have a very poor search and only have one suitable CB unit\n             available, this unit could be given as a single unit. This unit must have a TNC > 2.5\n             x 10^7 TNC/kilogram.\n\n          -  Haploidentical donors will be used as outlined in section 6.4. Related donors with up\n             to 8/10 match to the patient can be used Assignment of conditioning intensity (high\n             dose vs reduced intensity) will be based on patient disease status, age, extent of\n             prior therapy, organ function and presence of significant comorbidities as outlined\n             in Section 9.2.\n\n        For the purposes of analysis, patients will be assigned to Arms A and B as summarized\n        below according to their risk of early post-transplant death.\n\n        Eligible patients who fulfill all of the following criteria will be assigned to risk Arm\n        A:\n\n        Age 2-49 years Diagnosis Any acute leukemia in CR1 - CR2 (includes therapy-related and\n        arising from MDS or myeloproliferative disease). JMML in CR. CML with TKI failure & < 5%\n        blasts. MDS with < 5% blasts at work-up. Lymphoma (including CLL) CR1-2.\n\n        Performance Status Karnofsky > or = to 80; Lansky > or = to 80 Organ Function LVEF > or =\n        to 60% Spirometry & corrected DLCO > or = to 80% predicted. Total bilirubin normal; ALT/\n        AST normal-1.4 x ULN. Calc. creat. clearance > or = to 70 ml/min.\n\n        Prior HSC Transplant No HCT-CI score23 0-2 Pre-thaw TNC Dose Each unit > or = to 2.0 x\n        10^7/kg\n\n        Eligible patients who meet any of the following criteria will be assigned to risk Arm B:\n\n        Age 50-70 years Diagnosis Any acute leukemia in relapse/ refractory disease in BM or\n        circulating blasts or CR3 or aplasia. JMML not in CR. MDS with aplasia or > or = to 5%\n        blasts. Lymphoma (including CLL) with disease other than CR1-2. Severe myelofibrosis of\n        the bone marrow Performance Status Karnofsky 70; Lansky 70 Organ Function LVEF 50-59%.\n        Spirometry & corrected DLCO 50-79% predicted. Total bilirubin 1.1-1.5 normal; ALT/ AST\n        1.5-2.5 x ULN. Calc. creat. clearance 60-69 ml/min. Prior HSC Transplant Yes HCT-CI\n        score23 3 or higher Pre-thaw TNC Dose Either or both units 1.5-1.9 x 10^7/kg.\n\n        Exclusion Criteria:\n\n          -  Active CNS leukemia.\n\n               -  Any acute leukemia (including prior myelodysplasia or CML blast crisis) with\n                  morphologic relapse or persistent disease > 25% blasts in the BM, or doubling of\n                  the blasts in the blood in the 2 weeks preceding admission, or need for\n                  hydroxyurea in the 2 weeks prior to admission, or uncontrolled extra-medullary\n                  disease.\n\n               -  Two prior stem cell transplants.\n\n               -  One prior stem cell transplant within the preceding 6 months.\n\n               -  Prior radiation therapy rendering patient ineligible for TBI.\n\n               -  Uncontrolled viral, bacteria or fungal infection at time of study enrollment.\n\n               -  Sero-positive or NAT positive for HIV.\n\n               -  Females who are pregnant or breast feeding.\n\n               -  Patient or guardian unable to give informed consent or unable to comply with the\n                  treatment protocol including appropriate supportive care, follow-up, and\n                  research tests\n\n        Cord Blood Grafts:\n\n        Units will be selected based on the HLA-match to the patient and individual cell doses of\n        the units according to current MSKCC unit selection criteria. HLA-testing will be done\n        using molecular techniques. The standard cord blood graft for this protocol will consist\n        of 2 units as a double unit graft. Each unit will be at least 4 of 6 HLA-A, -B antigen and\n        -DRB1 allele matched with the recipient. Each unit will have a cryopreserved dose of at\n        least 1.5 x 10^7 TNC/recipient body weight (TNC/kg). In the occasional pediatric patient\n        with a large well matched good quality single unit or the rare patient with only one unit\n        of suitable match and dose characteristics the cord blood graft can consist of a single\n        unit.\n\n        Haploidentical Donor Inclusion Criteria:\n\n        A HLA-haploidentical related donor will be selected as available, and if possible using an\n        algorithm designed to maximize NK cell alloreactivity with prioritization according to\n        KIR/HLA genotypes.\n\n          -  Donor CMV status will also be taken into account.\n\n          -  The donor must meet criteria outlined in the FACT-approved SOP for \"DONOR EVALUATION\n             AND SELECTION FOR ALLOGENEIC TRANSPLANTATION\" in the Blood and Marrow Transplant\n             Program Manual, document E-1 (see attached, or link to URL:\n             http://mskweb5.mskcc.org/intranet/html/80312.cfm.).\n\n          -  The donor must have adequate peripheral venous catheter access for leukapheresis or\n             must agree to placement of a central catheter.\n\n          -  The donor must be >25 kg in weight.\n\n        Haploidentical Donor Exclusion Criteria:\n\n        Evidence of active infection (including active urinary tract infection, or upper\n        respiratory tract infection) or evidence of viral hepatitis exposure on screening unless\n        only HbsAb+ and HBV DNA negative.\n\n          -  Medical or physical reason which makes the donor unlikely to tolerate or cooperate\n             with growth factor therapy and leukapheresis.\n\n          -  Factors which place the donor at increased risk for complications from leukapheresis\n             or G-CSF therapy (e.g., active autoimmune disease, sickle cell trait, symptomatic\n             coronary artery disease requiring therapy).\n\n          -  Pregnancy (positive serum or urine \u03b2-HCG) or breastfeeding. Women of childbearing age\n             must avoid becoming pregnant while on the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682226", 
            "org_study_id": "12-153"
        }, 
        "intervention": [
            {
                "arm_group_label": "A: standard risk group", 
                "description": "7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)\n1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF", 
                "intervention_name": "CliniMACS Fractionation system (Arm A)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "B: high risk group", 
                "description": "8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3\n1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood\n1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF", 
                "intervention_name": "CliniMACS Fractionation system (Arm B)", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CYCLOPHOSPHAMIDE (CYTOXAN)", 
            "CYCLOSPORINE", 
            "FLUDARABINE", 
            "G-CSF", 
            "MYCOPHENOLATE MOFETIL (MMF)", 
            "Cord Blood Transplantation", 
            "CliniMACS", 
            "12-153"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Juliet Barker, MBBS", 
                "phone": "212-639-3468"
            }, 
            "contact_backup": {
                "last_name": "Katharine Hsu, MD, PhD", 
                "phone": "646-888-2667"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Juliet Barker, MBBS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies", 
        "overall_contact": {
            "last_name": "Juliet Barker, M.B.B.S.", 
            "phone": "212-639-3468"
        }, 
        "overall_contact_backup": {
            "last_name": "Katharine Hsu, M.D., Ph.D.", 
            "phone": "646-888-2667"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Juliet Barker, M.B.B.S.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The day of neutrophil recovery is defined as the first of 3 consecutive days in which the absolute neutrophil count (ANC) is > 0.5. The cumulative incidence of neutrophil recovery will be reported at day 45 post-transplant. Sustained neutrophil engraftment is neutrophil engraftment without secondary graft failure. This will be analyzed at 1 and 2 years post-transplant.", 
            "measure": "number of days to neutrophil recovery", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682226"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 year"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}